IXJ ETF Analysis
For informational purposes only. Not financial advice.
The IXJ ETF provides targeted exposure to global healthcare companies, focusing on established pharmaceutical and biotechnology firms. , IXJ offers a concentrated bet on the healthcare sector's leading players. The fund's dividend yield is 1.03%.
Given its concentrated nature and focus on large-cap healthcare, IXJ may appeal to investors seeking sector-specific exposure with a relatively low beta of 0.66, indicating lower volatility compared to the broader market. Past performance does not guarantee future results.
IXJ ETF — Price, Holdings & Analysis
ETF Overview
Risk Metrics
What does IXJ hold?
| Holding | Weight |
|---|---|
| Eli Lilly and Co (LLY) | 10.08% |
| Johnson & Johnson (JNJ) | 7.22% |
| AbbVie Inc (ABBV) | 4.95% |
| Roche Holding AG (ROG.SW) | 4.05% |
| AstraZeneca PLC (AZN.L) | 3.91% |
| Novartis AG Registered Shares (NOVN.SW) | 3.89% |
| Merck & Co Inc (MRK) | 3.71% |
| UnitedHealth Group Inc (UNH) | 3.21% |
| Amgen Inc (AMGN) | 2.52% |
| Abbott Laboratories (ABT) | 2.44% |
Dividend Yield
Risk Metrics
- Beta: 0.66
Questions & Answers
What is IXJ and what does it track?
IXJ is an ETF that provides investors with targeted exposure to leading global healthcare companies. It tracks an index composed of a select group of established pharmaceutical, biotechnology, and healthcare services companies.
This focused approach differentiates IXJ from broader healthcare ETFs that may include a wider range of companies and sub-sectors. As of 2026-03-15, IXJ offers a dividend yield of 1.03%.
What are the top holdings in IXJ?
IXJ's top holdings reflect its focus on established pharmaceutical and healthcare companies. As of 2026-03-15, the top three holdings are Eli Lilly and Co (LLY) at 10.08%, Johnson & Johnson (JNJ) at 7.22%, and AbbVie Inc (ABBV) at 4.95%.
These companies represent a significant portion of the fund's assets, highlighting the concentrated nature of IXJ's portfolio. Other notable holdings include Roche Holding AG (4.05%) and AstraZeneca PLC (3.91%).
Is IXJ a good long-term investment?
Whether IXJ is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and outlook on the healthcare sector. IXJ offers targeted exposure to leading global healthcare companies, but its introduces concentration risk.
The fund's beta of 0.66 suggests lower volatility compared to the broader market, but this does not eliminate the risks associated with its sector-specific focus.
How does IXJ compare to similar ETFs?
IXJ distinguishes itself through its highly, focusing on established global healthcare giants. Other healthcare ETFs may offer broader diversification across a larger number of companies or focus on specific sub-sectors like biotechnology or medical devices.
When comparing IXJ to similar ETFs, factors such as expense ratios, AUM (assets under management), and investment strategy may be worth researching.
Does IXJ pay dividends?
Yes, IXJ distributes dividends to its shareholders. As of 2026-03-15, IXJ has a dividend yield of 1.03%. This yield represents the annual dividend payment as a percentage of the fund's share price.
Dividends can provide a source of income for investors and contribute to overall returns. However, dividend yields can fluctuate over time depending on the performance of the underlying holdings and the fund's distribution policy.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
Written by machine, not reviewed page by page. Editorial oversight is systemic: the rules and the sources are checked, individual pages are not.